---

The ACRCelerate: Colorectal Cancer Stratified Medicine Network is a European-wide consortium of researchers at the forefront of CRC research. The overall aim of this project is to generate robust and reproducible preclinical data to de-risk future clinical trials based on patient stratification. The ACRCelerate partners work together to develop preclinical models that recapitulate the molecular subtypes of CRC and characterize their signaling pathways using DNA and RNA sequencing to subtype the models, as well as identify and test new therapeutics integrating data in a bioinformatic analysis pipeline. 

This partnership between Cancer Research UK (CRUK), Fundación Científica de la Asociación Española Contra el Cáncer (FC AECC), and the Fondazione AIRC per la Ricerca sul Cancro (AIRC), capitalizes on shared priorities across their respective research communities and is driven by a shared ambition to advance progress in translational research by building outstanding global networks. By bringing together renowned teams in the UK, Italy, and Spain, including VHIO, ACRCelerate harnesses the collective expertise of leading investigators to develop new resources and accelerate progress in collaboration. 

---

Cancer Core Europe (CCE) is a unique partnership aimed at addressing the cancer care - cancer research continuum challenge. Launched in 2014, this working consortium represents a critical mass of activity for the successful integration of all cancer care information, clinical research and outcome research, led by its founding partners and European comprehensive cancer centers of excellence: the Gustave Roussy (Villejuif, France), Cancer Research UK Cambridge Centre (Cambridge, UK), Karolinska Institutet (Stockholm, Sweden), Netherlands Cancer Institute – NKI (Amsterdam, The Netherlands), National Center for Tumor Diseases – NCT (Heidelberg, Germany) and The German Cancer Research Center (DKFZ), VHIO, as well as the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Milan, Italy).

CEE promotes the pooling and exchange of expertise, research findings, common platforms and processes, and empowers researchers and clinicians to rapidly exploit this trove of biological insights and clinical data for the benefit of patients.

www.cancercoreeurope.eu

---

CCE’s Basket of Baskets (BoB) trial is a modular, open-label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors. This study is carried out under the Cancer Core Europe (CCE) umbrella, with VHIO as trial sponsor.

This modular basket clinical trial consists of two parts: part A (iPROFILER), which includes the common procedures for tumor molecular profiling and treatment recommendation, and part B (iBASKET), which corresponds to the therapeutic portion. The purpose of part A is to assess participants’ tumor tissue in order to identify whether their respective tumors have certain mutations in cancer-related genes. This analysis provides information about potential targeted therapies that specifically attack those gene mutations. The purpose of part B is to offer participants a personalized anti-cancer treatment based on the detected gene mutations in tumors.

www.basketofbaskets.eu

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No. 101058620.

---

canSERV is an EU-funded project under the Horizon Europe programme to provide cutting-edge, interdisciplinary and customized oncology services across the entire cancer continuum. Incorporating 19 European partners including VHIO, it aims to offer a comprehensive portfolio of oncology-related research services available to all scientists in EU member countries, associated countries and beyond. 

This network combines expertise in the oncology development pipeline and seeks to foster a pan-European collaboration to promote innovative research projects and deliver precision medicine solutions for the benefit of cancer patients. Awarded through the HORIZON-INFRA-SERV call, canSERV will offer state-of-the-art services to the cancer research community in order to provide the necessary resources to develop new projects in personalized medicine. 

By connecting, coordinating, and aligning existing oncology and complimentary research infrastructures and providing services in a synergistic way transnationally, this project will capitalize on the critical mass of experts and services offered by the 13 research infrastructures that it brings together. 

Various VHIO groups are participating in this translational and multidisciplinary initiative including Joaquin Arribas’ Growth Factors Group, Violeta Serra’s Experimental Therapeutics Group, and out Stem Cells and Cancer Group led by Héctor G. Palmer, with Elena Garralda, Head of VHIO’s Early Clinical Drug Development Group and Director of our Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, as Principal Investigator of the project at VHIO.

www.canserv.eu

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No. 101058620.

---

CGI-Clinics aims at advancing personalized medicine in oncology by optimizing genomic data interpretation (after sequencing and before advising on compatible targeted therapies). Interpretation is a bottleneck for the full deployment and broad accessibility of Next Generation Sequencing (NGS) in the management of cancer. This project will address 3 main issues in genomic data interpretation, namely, it is not systematic, it deals with a majority of variants of unknown significance and fails to empower patients.

Cancer genomic data requires experts reviewing scattered databases and resources, in a time-consuming process that may lead to suboptimal clinical decisions. By integrating relevant public and private hospital databases, this project seeks to offer a one-stop shop solution that systematises tumour genome interpretation, to support medical doctors in choosing the most effective treatment for each patient, as well as facilitate virtual molecular tumor boards co-facilitated by reference hospitals. 

This project will be developed through three phases: a setup (assess needs), validation (pilot with the 9 clinical partners) and replication (30 hospitals across EU) and will enable the democratization of genomic data interpretation (independent of their size, resources and profiling technology), provide health economics validation, and universalize the interpretation of tumor genomes for personalized cancer medicine.

CGI-Clinics was awarded under the European Commission's HORIZON-RIA call. Led by the Institute for Research in Biomedicine (IRB, Barcelona) and VHIO, it brings together 17 project partners from four countries, including organizations representing patients, clinicians and researchers. VHIO’s role in the project counts on the leading participation of Ana Vivancos, Principal Investigator of our Cancer Genomics Group. 

www.cgiclinics.eu

This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05-02 under grant agreement No. 101057509.

---

The EU-funded CCE’s Building Data Rich Clinical Trials (CCE-DART), coordinated by VHIO, is carried out in collaboration with other leading experts from within the Cancer Core Europe Consortium (CCE). By harnessing and incorporating powerful cutting-edge technologies, methods and platforms, CCE-DART investigators will design and develop a new generation of data-rich, dynamic studies in oncology.

Building on the CCE-developed Basket of Baskets (BoB) investigator-initiated and adaptive trial which launched in 2018, CCE-DART further enhances BoB’s harmonized, molecular multi-tier profiling platform to more precisely match patients to novel anti-cancer medicines based on the genetic specificities of their individual tumors. In parallel, the researchers will continue to develop multiple treatments in genomically-selected populations.

www.cce-dart.com

This project has received funding from the European Union’s Horizon 2020 framework programme research under grant agreement No: 965397.

---

Launched in 2019, the OPTIMISTICC Cancer Grand Challenge – Opportunity to Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer, is a 5-year consortium funded by Cancer Research UK’s Grand Challenge, led by researchers at the Dana-Farber Cancer Institute-Harvard Medical School, and Harvard T.H. Chan School of Public Health (USA).

Aimed at better understanding the difference between a healthy microbiome and a microbiome associated with the development of colorectal cancer, the co-investigators from the US, Canada, UK, the Netherlands, and Spain, are seeking to identify ways to manipulate this collection of microorganisms to better prevent and treat cancer. It is thanks to the Grand Challenge funding that the project partners, including VHIO, are able to pool the necessary expertise in order to establish how the microbiome influences a cancer’s response to treatment, develop new treatments that alter the microbiome, and decipher how an individual’s external environment may affect their microbiome.

www.optimisticc.org

---

COLOSSUS – Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions, is a multi-center European Commission Horizon 2020-supported project powered by 13 leading clinical investigators and researchers spanning 7 European countries, with expertise in cancer immunology, systems biology, computational modelling, bioinformatics, omics analysis, clinical oncology/pathology, preclinical research, medical imaging, clinical trials, health economics and patient management.

This 5-year undertaking aims at better classifying and treating metastatic colorectal cancer (mCRC). Focused on microsatellite stable RAS mutant (MSS RAS mt) disease – a genetically identified type of CRC with very few therapeutic options available once patients develop resistance to existing chemotherapies, the COLOSSUS team seeks to expand and refine the classification of this particular subset of colorectal cancer.

www.colossusproject.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 754923.

---

EOSC4Cancer will make diverse types of cancer data accessible: genomics, imaging, medical, clinical, environmental, and socio-economic. It will use and enhance federated and interoperable systems for securely identifying, sharing, processing and reusing FAIR data across borders and offer them via community-driven analysis environments.

EOSC4 Cancer’s well curated data sets will be essential input for reproducible and robust analytics and computational methods – including machine learning and artificial intelligence. EOSC4Cancer’s five use cases will cover the patient journey from cancer prevention over diagnosis to treatment, laying the foundation of data trajectories and workflows for future European Cancer Mission projects.

The EOSC4Cancer consortium, jointly coordinated by the Barcelona Supercomputing Center (BSC, Barcelona) and ELIXIR (Cambridge, UK), comprises 29 partners, including VHIO, from 13 countries. Participating organizations include cancer research centers, research infrastructures, leading research groups, hospitals, supercomputing centers, as well as affiliated entities. 

To make the developments sustainable, EOSC4Cancer will leverage the partners’ research infrastructures partners and the EOSC ecosystem. It will also serve the European Cancer Mission, by engaging with large international coalitions (e.g., ICGC-Argo, GA4GH, 1+MG/B1MG, Cancer Core Europe, European Cancer Information System, European Network of Cancer Registries, Innovative Partnership for Action Against Cancer Joint Action) and patients/survivors associations.

www.eosc4cancer.eu

This project has received funding from the European Union’s Horizon program HORIZON-INFRA-2021-EOSC-01 under grant agreement No. 101058427.

---

EUCanCAN – the European-Canadian Cancer Network, led by the Barcelona Supercomputing Center (Spain), comprises a total of 18 partners from 5 different countries to pursue the homogeneous analysis, management and exchange of genomic-driven oncology data to advance precision medicine in cancer.

Jointly funded by the European Union’s Horizon 2020 research and innovation programme and the Canadian Institutes of Health, this project strives to provide a functional platform for federated genome analysis systems towards efficiently analyzing, managing, sharing and reusing mass genomic data at the global level. The participating reference nodes seek to process, store and share between 30-35 thousand patient samples across various tumor types.

This consortium also promises to drive discovery into robust and clinically-relevant patterns of genomic variation in cancer, including predictive biomarkers.

www.eucancan.com

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825835.

---

This project has received funding from the European Union's Horizon Europe Research and Innovation Programme HORIZON-MISS-2021-CANCER-02-02 under Grant Agreement No. 101096362.

Funded by the European Union’s Horizon Europe Research and Innovation Programme EUonQoL is a 4-year project that aims to develop, pilot and validate the EUonQoL-Kit, a patient-driven, unified system for the assessment of quality of life (QoL) based on evaluations and preferences of cancer patients and survivors.

Led by the Instituto Nazionale Tumori (Milan, Italy), the project partners including VHIOI, will develop the EUonQoL-Kit from a patient perspective, and will be administered digitally, available in the EU27 and Associated countries languages, and applicable in future, periodic surveys to contribute to the EU’s Cancer Mission.

At the core of the EUonQoL there is the adoption of a multistakeholder, co-design methodology, engaging patient representatives, healthcare professionals, administrators, policymakers, and citizens in all project related activities.

To be validated in a pilot survey using digital data collection within month 24 of the project, a total of 4,000 cancer patients and survivors will be enrolled through a network of EU cancer centers. An analysis of factors potentially impacting on cancer patients and survivors QoL, will also be performed. Implementation and exploitation strategies, as well as the linkage with other Cancer Mission projects and actions will be explored to develop future periodic surveys.

EUonQoL is composed by research institutions, cancer centres, as well as scientific, professional, and patient representative organizations, all with extensive experience and robust scientific background in the development of self-report QoL measures. This partnership fuels the ambition of EUonQoL to translate QoL information into future changes in cancer care policy and clinical practice.

www.euonqol.eu

---

The main objective of the EU-supported EURAMED ROCC-N-ROLL: EURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitization aspects, is to generate a European consensus on research needs and priorities in medical radiation applications and corresponding radiation protection to optimize the use of ionizing radiation in medicine.

Led by coordinating partner, the European Institute for Biomedical Imaging Research, Vienna (Austria), this pan-European consortium connects a total of 29 research centers, including VHIO. Taking the lead on radiation application in oncological diseases, VHIO is working with other experts in other settings including neurovascular as well as cardiovascular diseases, and explore relevant clinical scenarios, as well as provide patients’ perspectives.

Specifically, VHIO researchers are analyzing the needs of research in radiation application and corresponding radiation protection in oncology by identifying gaps and opportunities. Compile an overview of clinical situations that require the application of ionizing radiation in diagnosis and treatment, provide an outlook on envisaged future applications and trends in the oncology field.

www.cordis.europa.eu/project/id/899995

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 899995.

---

The EurOPDX Consortium – Translating Knowledge in Oncology, launched in 2013 to create a network of clinically relevant models of human cancer, and in particular patient-derived xenograft (PDX) models.

Connecting 18 cancer centers across 13 countries that are developing PDX cancer models, this initiative promotes the sharing and exchange of findings on promising therapeutics as well as leads multicenter preclinical studies. EurOPDX strives to reduce the duplication of efforts in oncology drug development and ultimately improve the quality of life and overall survival of cancer patients.

Supported by the European Union’s Horizon 2020 research and innovation programme and launched in 2018, EDIReX – EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts, is led by the EurOPDX Consortium counting on the research excellence of 19 entities -including VHIO- spanning 13 European countries.

The main aims of this project are to facilitate data exchange among academic and industrial preclinical and translational cancer professionals and, to spur and consolidate scientific collaborations in PDX research across Europe.

www.europdx.eu

The EDIReX project has received funding from the European Union’s Horizon 2020 research and innovation programme, grant agreement No. 731105.

---

I3LUNG is a five-year European project funded under the framework of the H2020 call: Ensuring access to innovative, sustainable and high-quality health care. The consortium gathers 16 partners, including VHIO, with different expertise located worldwide, with the common goal of providing optimal care and perosonalized treatment for patients affected by metastatic lung cancer. 

Thanks to the collection of biological, molecular, radiological, and clinical data from more than 2000 metastatic non-small cell lung cancer (mNSCLC) patients, I3LUNG will integrate all the collected information and thanks to the power of AI, generate a machine learning algorithm that will be able to predict the individual response to immunotherapy regimens. This tool will help to stratify mNSCLC patients and match tailored treatment to each case, moving lung cancer care away from a one-size-fits-all approach to more of a personalized treatment plan.

This individualized patient selection strategy will also help to reduce the European economic burden and improve patient outcomes by better matching available treatments to patients.

www.i3lung.eu

This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2021-CARE-05 under grant agreement No. 101057695.

---

Immune-Image is a 22 stakeholder-strong consortium incorporating public and private partners across 9 countries, including VHIO and the Vall d’Hebron Institute of Research (VHIR) from Spain.

Powered by the Innovative Medicines Initiative Joint Undertaking (IMI 2 JU), this initiative is led by Roche and coordinated by the Amsterdam University Medical Center (VUmC), the Netherlands. Set to run for an initial duration of five years, this project is entitled Specific imaging of immune cell dynamics using novel tracer strategies, and seeks to develop a novel non-invasive imaging strategy for assessing immune cell activation and dynamics in oncology and inflammatory disease.

Main deliverables include developing clinically validated radio-and optical immunotracers for the monitoring and measurement of immune cell presence, activation status and trafficking, and designing and implementing a ready-to-use sustainable molecular imaging platform, incorporating standardized protocols, best practices, quantitative image analyses, immune-based tracking design and development.

www.immune-image.eu

---

Immune4ALL is a 3-year project comprising 29 research groups and 215 researchers from 8 Spanish autonomous communities, encompassing three different areas of the CIBER – Centro de Investigación Biomédica en Red network (cancer, hepatic diseases, and rare diseases) and the National Biobank and Biomodel Platform. 

Aimed at exploring the feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors, this nationwide program is coordinated by Enrique de Álava, Virgen del Rocío University Hospital (University of Seville), and is structured around several pilot studies that include developing and validating these markers for immunotherapy and the generation of a computational framework for data processing analysis, filtering visualization, and clinical decision support aligned with IMPaCT. 

Focused on solid tumor types that cause high mortality, specifically in women, such as carcinoma of the breast, ovary, and cervix, or in both sexes, including hepatocellular carcinoma, bile duct carcinoma, GI-tract neuroendocrine tumors, and colorectal carcinoma, this project also has two general objectives devoted to social and economic perspectives (creating shared decision-making spaces with patients and generating cost-effective evidence) and training activities with patients and professionals in the field of precision medicine.

Immune4ALL’s strategy is to integrate leading groups with outstanding experience in clinical, translational, and technological research in the development and validation of immuno-oncology biomarkers (including Digital Pathology/Artificial Intelligence, liquid biopsy, and experimental models) and the development of personalized immunotherapies working in recognized institutes across Spain, under the umbrella of CIBER.

This project has been granted under the scope of the Proyectos de investigación de medicina personalizada program of the Instituto de Salud Carlos III (Institute of Health Carlos III – ISCIII).

---

---

IMPaCT – Infraestructura de Medicina de Precision asociada a la Ciencia y Tecnología, is a collaborative structure for the implementation of genomic medicine in the Spanish National Health System, coordinated by CIBER (Spanish Biomedical Research Networking Centers).

VHIO participates in Work Package 4, focused on cancer, and leads the unknown primary tumors part. WP4 aims to establish genomic methods to analyze tumors, create a portfolio of diagnostic services, standardize laboratory protocols and sample processing methods in order to establish variant interpretation guidelines and establish a clinical reporting model.

A network of high-capacity genomic analysis from existing centers will be established. This infrastructure will focus on rare diseases, cancers of unknown origin, and pharmacogenetics. This is a national program aimed at establishing standardized procedures to guarantee equitable access to genomic analysis. The Centre for Genomic Regulation (CRG), Barcelona, will be responsible for the centralization of samples.

www.impact-genomica.com

This project is funded by the Subdirección General de Evaluación y Fomento de la investigación dentro del Fondo Europeo de Desarrollo. Convocatoria Infraestructura de Medicina de Precisión Asociada a la Ciencia y Tecnología - IMPaCT. Ref: IMP/00009.

---

INGENIO - INtegrative GENomic, digital Imaging and clinical information towards precision Oncology optimization, is a 4-year interdisciplinary program aimed at boosting precision oncology through the implementation of predictive biomarkers, digital imaging and pathology, as well as artificial intelligence (clinical and genomic).

Main goals include the development of a CIBER (Spanish Biomedical Research Networking Centers) platform that integrates data on biomarker determination and clinical outcomes in lung cancer, advancing digital imaging (pathology and radiomics) and validation for precision oncology, validating new technologies and strategies for clinical and biomarker implementation, and evaluating emerging biomarkers in other solid tumors. Program partners, including VHIO, will also seek to test clinical intervention in agnostic targets, and establish a strategy for the creation and implementation of a Molecular Tumor Board (MTB).

INGENIO comprises groups with predominant experience in clinical and translational research in biomarker assessment, personalized patient care, digital imaging, artificial intelligence and data science, from research centers of excellence across Spain belonging to the CIBER network.

This project is funded by a grant received from the Carlos III Institute of Health (ISCIII) for personalized precision medicine research projects, as part of the Strategic Action in Health (AES) 2017-2020.

---

Coordinated by the Josep Carreras Leukemia Research Institute, Barcelona (Spain), the EU-funded Interreg POCTEFA PROTEOblood Consortium is co-funded by the European Regional Development Fund/European Social Fund, and aims to optimize, share and exploit latest technologies for the study of protein homeostasis in two prevalent subtypes of leukaemia and lymphoma: acute myeloid leukemia (AML) and diffuse large b-cell lymphoma (CLBCL) in the POCTEFA region (Spain-France-Andorra).

Comprising six other partners - CIC bioGUNE, IQS, CNRS, INSERM, Anaxomics Biotech, and VHIO, the investigators use modelling collections from patient-derived studies to recreate the tumor microenvironment ex vivo, and apply innovative proteomic approaches associated with system biology analysis and small molecule design, to facilitate the complete characterization of proteopathies and development of more effective therapies to be validated through xenoinjerts.

http://proteoblood.eu/ The project has been co-financed by:

The European Regional Development Fund (ERDF) through the Interreg V-A Spain-France-Andorra Programme (POCTEFA 2014-2020) – Ref: EFA360/19.

European Regional Development Fund/European Social Fund.

---

Funded by the European Union’s Horizon 2020 research and innovation programme, the CELAC and European Consortium for a Personalized Medicine Approach to Gastric Cancer (LEGACy) is a 4-year project led by the INCLIVA Health Research Institute (Spain), in partnership with 11 other members across 9 different countries including VHIO.

Focused on advancing personalized medicine against gastric cancer, this project aims to improve diagnosis and treatment by using data obtained through extensive research in four EU countries and four countries within the Community of Latin American and Caribbean (CELAC) States.

Seeking to improve patient outcomes by applying personalized medicine at the three levels of prevention, this consortium implements a personalized medicine strategy at the first level of prevention, improves early gastric cancer detection at the second level of prevention, and improves treatment through the identification of high-risk populations. www.legacy-h2020.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825832.

---

MESI-STRAT combines the expertise of 15 partners from 7 European countries to establish the interplay of breast cancer metabolism and oncogenic signaling (Metabolic Signaling) by systems medicine approaches.

Aimed at developing new models for knowledge-based STRATification of patients into subgroups with different endocrine therapy resistance mechanisms, this pan-European 57-month project, supported by the European Union’s Horizon 2020 research and innovation programme, represents an important forward step towards improving outcomes for these patients.

The team pioneers breast cancer metabolism as a novel approach for the stratification of patients, tracking of resistance and better guiding clinical decision-making throughout the course of endocrine therapy. Through the development of new computational models in combination with network analyses, pharmacogenomics and integrated multi-omics data, MESI-STRAT aims at better deciphering the metabolic and signaling networks that drive resistance to endocrine-based therapies.

www.mesi-strat.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754688.

---

The MIRACLE project has been awarded under the ERA PerMed Joint Transnational Call 2021: Multidisciplinary research projects on personalized medicine – development of clinical support tools for personalised medicine implementation. This consortium comprises 5 partners and is jointly led by Paola Ulivi, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS, Italy), and VHIO’s Enriqueta Felip. 

MIRACLE - A machine learning approach to identify patients with resected non-small-cell lung cancer with high risk of relapse, aims to develop and validate a machine learning algorithm acting as a clinical decision support tool for disease free survival prediction based on joint analysis of biological, clinical, and radiologic features.

---

Aimed at revolutionizing Artificial Intelligence (AI) in healthcare using Swarm Learning (SL), the 5-year EU-funded ODELIA research project: Open Consortium for Decentralized Medical Artificial Intelligence, will establish the first pan-European SL network that allows for privacy conserving training of medical AI algorithms with the true democratic participation of all 12 partners from across Europe including VHIO (academic institutions and industry partners). 

Through this network, AI algorithms will be developed and validated for the detection of breast cancer in magnetic resonance imaging (MRI) screening examinations as a demonstration case. Training clinically useful AI models usually requires sharing of patient related data which often faces several obstacles. This problem has been tackled by federated learning (FL). However, in FL AI models are combined by a central coordinator requiring participants to relinquish control over the AI model, concentrating control and commercial exploitation in a single actor. This limitation has been addressed by swarm learning, in which AI models are trained decentrally and models are combined without the requirement for a central coordinator. SL in medical AI has never previously been applied in a real-world large-scale setting, which is the main objective of ODELIA.

This pan-European academic and clinical consortium will develop, implement and evaluate SL-based workflows to train AI models in medical imaging, in particular- and as an exemplary demonstration case - in the context of breast cancer screening. A blockchain will be created to enable institutions across Europe to jointly train AI models without having to share their data or rely on a central coordinator.

www.eibir.org/projects/odelia/

The ODELIA project receives funding from the European Union’s Horizon Europe and innovation programme HORIZON-HLTH-2021-CARE-05 under grant agreement No. 101057091.

---

The EU-funded ONCNGS project aims to tackle a common, unmet need in oncology; namely to profile multiple tumor types at the molecular level in the broadest possible way and establish an economically sustainable and de-centralized model that facilitates secure and transparent access to sensitive data.

ONCNGS challenges the market to research and develop novel, affordable solutions to provide the best NGS tests for all solid tumor and lymphoma patients. The challenge consists of providing efficient molecular DNA/RNA profiling of tumor-derived material in liquid biopsies by means of a pan-cancer tumor marker analysis kit including NGS analysis integrated with an ICT decision support system, and an analytical test for interpretation and reporting.

www.oncngs.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874467.

---

ONCODISTINCT is a research network that brings together leading academic investigators with a shared vision for innovative clinical research.

Established by several cancer institutes in and outside of Europe, this network comprises a multidisciplinary group of investigators with expertise in early drug development and clinical research.

Together, they aim to address the current challenges in oncology and improve patient outcomes by designing and conducting innovative clinical studies, and accelerating the development of anti-cancer medicines in solid tumors, particularly in settings with unmet medical needs.

ONCODISTINCT currently connects 28 cancer centers and university hospitals, and fosters collaborations between oncologists, organ specialists, radiotherapists and scientists across the ONCODISTINCT sites, as well as pharmaceutical companies. Established seven years ago, the network is dynamically evolving as it continues to incorporate new clinical centers as well as think tank institutes as members.

www.oncodistinct.net

---

Recent findings have shown that some RNA molecules previously annotated as non-protein coding actually contain small open reading frames that code for evolutionary conserved, unannotated, micropeptides. The few micropeptides characterized to date play key functions in fundamental processes such as DNA repair, muscle physiology and regeneration. However, the relevance of micropeptides in cancer and metastasis has not yet been defined. 

Their small molecular size makes them ideal candidates to be shed into tumor-derived exosomes. Exosomes are small vesicles containing peptides, proteins and genetic materials such as small RNAs that are secreted by many cancer types. Recent data demonstrate that exosomes secreted from pancreatic cancer cells can be used as surrogate markers of metastasis and prepare pre-metastatic niches in the liver. 

The OncoExoPeptides project’s hypothesis is that exosome-secreted micropeptides are novel biomarkers secreted by pancreatic cancer cells and play an active role in tumor-microenvironment communication and metastasis. To date, we have discovered 6 novel micropeptides dysregulated in cancer that have tumor suppressor activities. Here, we propose an innovative research program to: (1) identify exosome-secreted micropeptides involved in tumor communication; (2) detect exosome-secreted micropeptides in patient-derived plasma; (3) characterize their function in pancreatic cancer; and (4) establish novel prognostic signatures and stratification tools.

To do so, this collaboration gathers a multidisciplinary team including the expertise of VHIO’s Maria Abad in micropeptides, Hector Peinado, Spanish National Cancer Research Center (CNIO, Madrid, Spain) in exosomes, and Bruno Costa-Silva, Champalimaud Foundation (Lisbon, Portugal) in liver pre-metastatic niches, pancreatic cancer clinicians and experts in proteomics and biocomputing. This project will advance insights into the unexplored field of the exosome-secreted micropeptides and may facilitate the development of new therapeutic strategies in oncology.

---

PCM4EU – Personalised Cancer Medicine for all EU Citizens, is a project under the Europe’s Beating Cancer Plan by EU4Health and comprises partners from 15 countries across Europe, including VHIO. Centered on facilitating the implementation of molecular cancer diagnostics for precision oncology such as DRUP-like clinical trials, PCM4EU is coordinated by Hans Gelderblom at the Leiden University Medical Centre (LUMC), the Netherlands.

PCM4EU is divided into six workpackages (WPs): WP2 focuses on mapping and facilitating the use of molecular cancer diagnostics, and WP3 involves precision oncology and promoting and initiating more national DRUP-like clinical trials in European countries. WP4 is dedicated to implementing precision oncology and standards for use in diagnostics and molecular tumour boards (MTBs) in European countries. WP5 promotes equitable and cross-border access, and WP6 focuses on the training of the next generation of oncologists. PCM4EU also includes a patient engagement strategy to ensure access to molecular-based clinical trials and will also build a data aggregation platform. VHIO participates in WP2, WP3 and WP5.

The PCM4EU project receives funding from the European Union’s Horizon Europe and innovation programme HORIZON-HLTH-2021-CARE-05 under grant agreement No. 101057091.

---

PERSIST-SEQ is a public-private partnership funded by the Innovative Medicines Initiative (IMI), with representation from academic institutions, small- and medium-sized enterprises, public organizations and pharmaceutical companies.

The PERSIST-SEQ five-year international collaboration, led by the Oncode Institute (Utrecht, The Netherlands) and AstraZeneca, comprises 14 partners including VHIO and aims to provide the cancer research community with a new gold standard workflow for single-cell sequencing by developing and validating best practices as well as generating and analyzing high-quality FAIR data.

Empowering the scientific community to unravel therapeutic resistance and develop smarter therapeutic strategies to better treat cancer and prevent drug resistance, PERSIST-SEQ will employ an open access model to build and sustain its benchmarking procedures and centralized European data infrastructure. This model reduces duplication of efforts, thereby promoting collaboration across disciplines and ensuring efficient adoption of state-of-the-art single cell technologies.

www.persist-seq.org

PERSIST-SEQ is funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 101007937. This Joint Undertaking receives support from the European Union’s Horizon 2020 research an innovation programme and EFPIA.

---

The PhD PI3K biology in health & disease network incorporates 10 academic, clinical and industrial partners with renowned expertise in research focused on PI3K signaling. Leading a unique training network, this collaboration connects complementary expertise and brings additional value, novel tools and leadership of excellence in order to train talented early-stage researchers and suitably equip them for leading roles in cancer science and drug discovery in European industry and academia.

This research training program not only represents unparalleled educational opportunity for these young scientists, but also aims to increase the international competitiveness of European research in PI3K discovery and drug development.

www.pi3k-phdproject.eu

---

Coordinated by the Instituto de Investigação e Inovação em Saúde da Universidade do Porto (Porto, Portugal), the 3-year PREVENTABLE consortium is funded by the European Commission under the topic HORIZON-HLTH-2022-CARE-08-04 - Better financing models for health systems, and comprises 10 partners, including VHIO, in 8 countries. 

The main aim of this project is to merge specialized clinical knowledge on rare tumor risk syndromes (RTRS) pathways of care, real-life clinical data from RTRS patients and experiences from professionals and patients, with health economic models and social sciences approaches to estimate the cost-benefit of risk-reduction interventions in RTRS and delineate guidelines for its communication among and within clinical teams and RTRS patients. 

PREVENTABLE project results will be delivered to a diversity of stakeholders, including policy-makers, in order to promote the implementation of cost-effective RTRS patient-centered care in Europe.

The PREVENTABLE project receives funding from the European Union’s Horizon Europe and innovation programme HORIZON-HLTH-2022-CARE-08 under grant agreement No. 101095483.

---

PROMISE - BioPrinted hydrogel MicrofluidicS to mimic patient-specific tumor mEtastatic microenvironment is a project coordinated by IBEC (Institut de Bioenginyeria de Catalunya) that wants to put 3D bioprinting at the service of improving the survival of cancer patients.

3D bioprinting enables the generation of three-dimensional cell models that imitate the human physiology to test new therapeutic strategies in the laboratory. These models can accurately mimic the patient’s specific tumor and its surrounding environment.

This project, which combines 3D bioprinting and advanced liquid biopsy techniques in an organ-on-a-chip device, seeks to provide physicians with new tools to understand and monitor disease evolution in patients with metastatic colorectal cancer aimed at improving survival rates.

VHIO participates in the clinical validation of this microfluidic platform based on hydrogels that mimic the tumor microenvironment on cells derived from patients with metastatic colorectal cancer. We will validate this technology in specific patient cohorts.

---

RAD51predict – Patient stratification based on DNA repair functionality for cancer precision medicine, is an ERAPerMed funded project led by VHIO. It aims to establish the prevalence of functional HRR deficiency (HRD) and its predictive value for personalized treatment with platinum salts and PARPi in breast cancer, ovarian cancer, prostate cancer, and endometrial cancer using the RAD51 immuno-assay and genomic assays.

This project seeks to perform an economic evaluation of selecting patients for PARPi treatment based on the RAD51 assay, genomic assays, or the current selection criteria to provide functional validation of germline/somatic genetic variants of unknown significance (VUS) using patients’ data, cell lines and assessment of HRR markers in the tumor; integrate functional HRD data into existing public genomic databases; transfer the RAD51 assay as a predictive test in the clinic, and develop multiplexed protocols, automatization of image analysis, and real-time monitoring in circulating tumor cells.

This project is supported by the ERAPERMED2019-215 award, granted by Fundación Científica de la Asociación Española Contra el Cáncer (AECC FC) and by the Instituto de Salud Carlos III (ISCIII) through the Acción Estrategica en Salud (AES) 2019, both within the ERA PerMed framework.

---

Incorporating a network of 27 research entities spanning 10 countries, SPECTAcolor - Screening Platform for Efficient Clinical Trials Access in Colorectal cancer, is an initiative within the framework of the research program of the EORTC, supported by Alliance Boots.

Launched in 2013, this is the first prospective fully annotated tumor samples Biobank and Biomarker analysis platform for the genetic profiling of patients suffering from advanced colorectal cancer.

www.eortc.org/blog/category/spectacolor

---

Through the ERA-NET Sustained collaboration of national and regional programmes in cancer research activities, the Spanish Association Against Cancer (AECC) and Institute of Health Carlos III (ISCIII) awarded VHIO with two TRANSCAN-3 projects funded by the EU's Horizon Europe framework program in 2021, officially granted in 2022. 

Supported by the Joint Transnational Call for Proposals Next Generation cancer immunotherapy: targeting the tumour microenvironment, the first proposal entitled Evaluating the therapeutic potential of immunosuppressive paracrine cytokines in the tumour microenvironment of metastatic lesions (IParaCyts), is coordinated by Joan Seoane, co-Director of VHIO’s Preclinical and Translational Research Program . This project aims to advance and apply insights into druggable paracrine cytokines that interfere with immunotherapy in liver metastasis, addressing these matters in an integrative fashion based on the specific expertise of our partnership. 

The second project entitled Artificial Intelligence-based end-to-end prediction of cancer immunotherapy (TANGERINE), is coordinated by Raquel Perez-Lopez, Principal Investigator of VHIO’s Radiomics Group. 

Both projects are supported by TRANSCAN-2 JTC 2021 and granted by the Fundación Científica de la Asociación Española Contra el Cáncer (FCAECC) and the Instituto de Salud Carlos III (ISCIII) through the Acción Estratégica en Salud (AES) 2021, within the TRANSCAN-2 framework. 

TRANSCAN-2 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 643638.

---

The European Commission has launched the Cancer Mission as one of five missions to boost research and innovation through funding under the Horizon Europe programme. The aim of the Cancer Mission is to improve the life expectancy and quality of life of more than 3 million patients by 2030, through prevention measures, early detection and more effective treatments.

Implementation plans of two convergent European initiatives, the Horizon Europe Mission Cancer and the Europe’s Beating Cancer Plan, spur for a European Initiative to UNderstand CANcer - UNCAN.eu. More precisely, the UNCAN.eu initiative is one of the 13 specific objectives of the Mission on Cancer and one of the ten flagships of the Europe’s Cancer Beating plan. The Coordination and Support Action (CSA), named 4.UNCAN.eu, is planned to generate a blueprint for UNCAN.eu.

The blueprint for UNCAN.eu will propose to set up a European Federated Cancer Research data hub and to generate a series of use cases, addressing major challenges in cancer research. These ambitious and innovative, but realistic and focused, use cases will be cross-border and trans-disciplinary research programs built in a problem-solving manner. Results of these use cases will feed the Cancer Research data hub with findable, accessible, interoperable, and re-usable (FAIR) cancer research data.

4.UNCAN.eu is coordinated by Eric Solary, Gustave Roussy Cancer Campus, Grand Paris (France), and with the participation of VHIO and the CIBERONC network as Spanish representatives. VHIO’s Director Josep Tabernero is leading one of the six work packages to develop a methodology to identify translational cancer research lines to be prioritized and funded by the European Commission until 2027. 

https://uncan.eu/

The UNCAN.eu initiative receives funding from the European Union’s Horizon Europe and innovation programme HORIZON-MISS-2021-UNCAN-01-01 under grant agreement No. 101069496.

---

UpSMART Accelerator seeks to improve experimental cancer development across the UK, Italy, and Spain, by providing early-phase clinical teams with digital healthcare products (DHP) for the real-time access to a wealth of patient data, and thus enable faster decision making. 

The UpSMART Consortium consists of 23 participating institutes across Experimental Cancer Medicine Centres (ECMCs) in the UK, and Early Drug Development Units (EDDUs) in Spain and Italy. The program will test existing digital tools at these 23 phase I Units.

UpSMART will develop and provide all clinical sites with free to use access to new digital healthcare technology tools and improved approaches in trials that enable patients’ access to tomorrow’s medicines today. This project promotes the wider scale sharing and implementation of digital healthcare products as well as training in digital healthcare product approaches.

upsmart.digitalecmt.com

The program was awarded a Cancer Research UK (CRUK) Accelerator Award.

---

Announced in 2018, one of the U.S. Department of Defense’s (DoD) Innovative Minds in Prostate Cancer (IMPaCT) Awards, funds a four-year collaborative partnership to advance precision medicine against metastatic prostate cancer (mPC). This coalition counts on the multidisciplinary expertise of investigators at VHIO, the Spanish National Cancer Research Center – CNIO (Madrid, Spain), and the University of Washington (USA).

Aimed at more precisely gauging response in patients to standard therapies, the team is developing new, more effective and tailored treatment strategies, as well as designing a clinical trial to assess the performance of a DNA damaging platinum chemotherapy, carboplatin, that is already used to treat other tumor types including ovarian and breast cancer.

https://cdmrp.army.mil/pcrp

---

WIN - Worldwide Innovative Networking in personalized cancer medicine, initiated by the Institut Gustave Roussy (France) and The University of Texas, MD Anderson Cancer Center (USA) is a non-profit, non-governmental organization incorporating 39 leading organizations representing all stakeholders in personalized cancer medicine covering 21 countries and 4 continents, united by their vision to deliver on the promise of effective, personalized cancer medicine to patients worldwide.

Under the tagline WINning together, WIN was formed on the premise that members can accomplish more together than each organization can achieve working alone. Aimed at improving cancer patients’ survival and quality of life, WIN members also collaboratively design and carry out global studies designed to achieve breakthroughs for cancer patients across the globe.

www.winconsortium.org

---

Newly launched consortia in 2023

---

AI4Lungs is a project funded under the HORIZON Call for Tools and Technologies for a Healthy Society (two-stages 2022). The consortium gathers a total of 18 partners, from which VHIO is a member, intending to develop and validate AI-based tools and computational models which will improve patient stratification to optimise the diagnosis and treatment of respiratory diseases.

With the usage of multiple data sources from clinical partners, as well as the registries and open national and international databases, AI4Lungs will enable patients to benefit from global data and knowledge sharing, to ensure a more accurate diagnosis and treatment planning. By scaling up, AI4Lungs will end up supporting any patient from any country and any hospital.

This project will reduce costs and efforts from the health system by avoiding unnecessary testing, ineffective treatments and emergency services, thus optimizing the use of health technologies and resources.

https://www.ai4lungs.eu

This project has received funding from the European Union’s Horizon program HORIZON-HLTH-2022-TOOL-12-two-stage under grant agreement No. 101080756.

---

CARE1 has been funded under the Pragmatic Clinical Trials to optimise treatments for patients with refractory cancers Call. The consortium is made of 15 participants, including VHIO, to build a large-scale platform to define therapy guidelines based on new biomarkers. This action is part of the Cancer Mission cluster of projects on Diagnosis and Treatment.

The CARE group is a European initiative of European RCC physicians who have gathered to define high-priority topics in academic research and launch dedicated trials, given the high number of cases of Renal Cell Carcinoma (RCC), and subsequent deaths.

CARE-1 is a prospective randomized phase III study, whose primary endpoint is comparing overall survival when using the two different types of combination therapy utilized nowadays as the standard of care, to define the optimal combination.

https://www.gustaveroussy.fr/en/care1-european-study-first-line-treatment-metastatic-kidney-cancer

This project has received funding from the European Union’s Horizon program HORIZON-MISS-2022-CANCER-01 under grant agreement No. 101104801.

---

Incorporating a network of 54 research entities, and spanning 27 European Member States and 5 Associate Countries, the Comprehensive Cancer Infrastructures 4 Europe (CCI4EU), is an EU-funded project under the call Strengthening Research Capacities of Comprehensive Cancer Infrastructures. The consortium of which VHIO is a member, was created to reduce disparities in research by developing a cancer care programme with an inclusive approach.

This project was thought of due to the imparities between and within countries in terms of access to research, innovation and quality care when talking about cancer, exacerbated by the fact that it is the second leading cause of death in Europe and has an expected increase of about 2% by 2035.

A European initiative based on a Capacity Building Programme will be implemented in all Member States, in the context of other actions ongoing, such as CRANE, JANE and UNCAN. This initiative will operate at an Individual, Institutional and Systemic level, and it will maximize its impact by bridging with the work of ongoing EU cancer research projects. Furthermore, this initiative will be supported by an education programme.

https://cci4eu.eu

This project has received funding from the European Union’s Horizon program HORIZON-MISS-2022-CANCER-01 under grant agreement No. 101103746.

---

Implementing inter-specialty cancer training in 100 centres across Europe (INTERACT-EUROPE 100) is a project funded under the Call EU4Health Programme 2021-2027 – a vision for a healthier European Union as part of Europe’s Beathing Cancer Plan. The consortium is formed by 38 partner organisations, of which VHIO is a member.

This project builds upon the work done by INTERACT-EUROPE, its predecessor, and it aims to provide cancer care professionals with inter-speciality cancer training (ISCT), by fostering stronger collaboration among its providers and equipping professionals from various specialities with the skills needed for more effective collaboration. 

This project aligns seamlessly with the principles laid out in the European Code of Cancer Practice, as it aims to deliver the best possible outcomes for patients.

This project has received funding from the EU4H-2022-PJ.

---

The Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumour Infiltrating Lymphocytes (TIL in selected solid tumours (PragmaTIL) is a project funded under the Pragmatic Clinical Trials to optimise treatments for patients with refractory cancers Call. The consortium is comprised of 12 participant centres, from which VHIO is the coordinator and it aims to optimise the treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) to improve the clinical implementation of this treatment modality in academic hospitals.

PragmaTIL intends to reduce the treatment-related toxicities associated with high-dose interleukin 2 while maintaining the efficacy, and therefore achieve better clinical management of patients and enhance their quality of life, which are the main barriers when applying this treatment method.

This project intends to better societal opinion of these therapies, having therefore a global impact which will help in future research projects.

https://pragmatil.eu

This project has received funding from the European Union’s Horizon program HORIZON-MISS-2022-CANCER-01 under grant agreement No. 101104684.

---

The PRecisIon Cancer Medicine RepurpOsing SystEm Using Pragmatic Clinical Trial (PRIME-ROSE) is a project funded under the Pragmatic clinical trials to optimise treatments for patients with refractory cancers Call. This project has a total of 24 members, between participants and partners, of which VHIO is one of them, to optimise treatments and enhance the quality of life.

This consortium uses the clinician-initiated family of DRUP-like innovative trials which provide access to precision medicine for cancer patients. It relies on drug rediscovery protocol-like protocols, ensuring a clinician-driven approach to bring to the forefront of cancer care precision medicine.

The project aims to contribute to the Mission Cancer goal by optimising treatment and supporting the quality of life of more than 3 million people by 2030 falling under the cluster of projects on Diagnosis and Treatment.

https://www.matrix-fkb.no/en/prime-rose/home

This project has received funding from the European Union’s Horizon program HORIZON-MISS-2022-CANCER-01 under grant agreement No. 101104269.

---

The SAGITTARIUS Trial – A precision medicine trial leveraging blood-based tumour genomics to optimize treatment in operable stage III and high-risk stage II colon cancer patients, is a project funded under the Call for Pragmatic clinical trials to optimise treatments for patients with refractory cancers, which has 9 participants, including VHIO. The project aims to optimize the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC).

It has been seen that almost half of all LRCC patients relapse within two years of surgery due to micro-metastatic residual disease (MMRD), which is undetectable through imaging. SAGITTARIUS will deploy a ctDNA assay to detect the absence, presence, or persistence of MMRD, as it has been seen in retrospective studies that its detection after surgery predicts cancer recurrence with high sensitivity and specificity. 

The diagnosis of MMRD will help in guiding and personalising therapeutic interventions, and it will reclassify how the disease is perceived by clinicians.

https://sagittarius-horizon.eu/en/

This project has received funding from the European Union’s Horizon program HORIZON-MISS-2022-CANCER-01 under grant agreement No. 101104657.

---

The UNIQUE Platform (UNderstanding cancer through sIngle cell seQUEncing), is a proposal funded by Fundació “la Caixa” under the Caixa Research Strategic Projects – Infrastructures. This project coordinated by VHIO will launch a pioneering research platform for understanding complex biological processes. 

Tumour heterogeneity is a major issue that limits the efficacy of targeted therapies and compromises treatment outcomes. Through the use of single-cell sequencing technologies, which are cross-cutting technologies that help in understanding cancer pathophysiology, we will be allowed to detect and characterize rare stem cell populations present in the tumour microenvironment (TME) which are responsible for therapy resistance and tumour relapse, dormant tumour cells driving metastasis, low-abundance CTCs and immune cells that may hold functional relevance and clinical significance.

Thus, the UNIQUE platform will enable the detection and monitoring of the genotype and the molecular phenotypes at a single-cell resolution, overcoming the lack of it in bulk analyses.

This project has received funding from Fundació “la Caixa”.

---

MucOncoBots is the Drug-loaded nanobots for transmucosal delivery to mucinous tumours proposal, funded under the ERC-2023-POC. VHIO is one of the beneficiaries of this project, which aims to assess the use of transmucosal delivery of anti-cancer drugs as opposed to the standard of care to treat pseudomyxoma peritonei (PMP), a mucus-secreting tumour.

This project will utilise patient-derived organoids and xenografts from PMP patients, to analyse whether the nanobots used can overcome the mucus barrier to treat PMP. Furthermore, some of these patients have been shown to present oncogenic BRAFV600E mutations, thus introducing a new druggable targeted mutation.

A comparative study will be performed to assess the treatment’s efficacy compared to the standard of care to ensure the translation of the results to the clinic. 

This project has received funding from the ERC Proof of Concept Grant provided by the European Research Council under grant agreement No. 101138723.

---

TACTIC is a consortium funded by FORTALECE, within the State Subprogram for Institutional Strengthening, included in the State Program to Promote Scientific and Technical Research and its Transfer.

FORTALECE aims to fill those spaces left by conventional calls for research projects and human resources, to promote the qualitative transformation of research activity while simplifying certain administrative processes.

The main objectives of the call are as follows: Strengthening existing research and innovation lines at the Health Research Institutes (IIS); Promoting the generation of cutting-edge scientific knowledge aimed at improving health and addressing society's main health challenges; Promoting balanced development of actions from both consolidated research groups and emerging research groups; Addressing citizens' health priorities, both in preventive, diagnostic, curative, rehabilitative, and palliative aspects of diseases, and in generating scientific evidence as one of the bases for the quality of care and prevention in the National Health System (SNS), playing a key role in the structuring of the public R&D&I system in Biomedicine and Health Sciences.

The research of the Vall d'Hebron Barcelona Hospital Campus is driven through the Accredited Health Research Institute Research Institute (IIS IR-HUVH). IISIR-HUVH has been awarded the TACTIC project within the FORTALECE call.

TACTIC: TACkling healthcare challenges through disruptive science, novel Therapies and systems medicine.

The objective of the Project is to address health challenges through disruptive science, novel therapies, and systemic medicine. TACTIC tackles the strategic health challenges of non -communicable diseases (NCDs) and Rare Diseases (RDs) to strengthen research based on Systems Medicine (focused on patient-centered, primary care, transfer and impact, and translational research), including two complementary cross-cutting axes: To develop new perspectives for personalized and precision medicine in the fields of cancer, cardiovascular and neurological disorders, and rare diseases from childhood to adulthood.

---

Other collaborations

---

The AstraZeneca/MedImmune – VHIO Alliance drives advancements at the preclinical, clinical and translational research levels across AstraZeneca's oncology portfolio. Combining VHIO's strengths in promoting cancer discovery through the integration of translational science and clinical research with AstraZeneca's promising early-stage oncology pipeline, the alliance focuses on areas including DNA damage repair, drug resistance, new drug combinations and molecular profiles for patient selection.

In 2020, AstraZeneca/Medimmune announced its Partner of Choice Network, comprising nine of the world’s most renowned research centers and institutes in oncology to accelerate research against some of the most difficult-to-treat cancers. Selected partners of choice are the Cambridge Cancer Center (UK), Institut Gustave Roussy (France), Johns Hopkins University (USA), Memorial Sloan Kettering Cancer Center (USA), Oregon Health and Science University/Knight Cancer Institute (USA), Peter MacCallum Cancer Center (Australia) Princess Margaret Cancer Center (Canada), University of Navarra (Spain), and VHIO.

This network serves a forum for data sharing and cancer discovery in real-time. Scientific insights and findings generated through clinical studies are exchanged among partner institutions for the development and implementation as best practices in oncology. AstraZeneca will support selected clinical and non-clinical research proposals from the partners’ investigators to expedite novel scientific research and innovative clinical trial design aimed at developing new strategies in precision medicine against cancer.

www.astrazeneca.com

---

Launched by Roche in 2016, the imCORE - immunotherapy Centres of Research Excellence Network is a 27 partner-strong collaboration that aims to advance discovery in cancer immunotherapy. It connects internationally renowned scientific and clinical experts in immune-based therapeutic strategies in oncology who work together to assess and advance the most promising novel treatment approaches.

Working in collaboration with scientists from Roche and Genentech, researchers and physician-scientists in cancer immunotherapy from across the globe aim to drive the application and extension of immune-based strategies to more tumor types, as well as advance insights into the cellular and molecular mechanisms modulating immune response to cancer.

This network was designed to significantly advance anti-cancer immunotherapeutics and accelerate discovery towards benefiting patients who may stand to gain from novel immune agents as mono therapy or in combination.

www.roche.com

---

The SCITRON Consorcio público-privado de Investigación Científica y Translacional en Oncología (Consortium for Scientific Translational Research in Oncology) is a scientific program which was established in collaboration with Novartis in 2017.

As a new model of R&D collaboration, this initiative connects experts from Novartis and VHIO in applied and translational research to increase the impact of basic research in clinical practice. The specific areas of interest include the development of a technology platform that analyses tumor clonal evolution and resistance mechanisms to targeted immunotherapy.

www.novartis.com

---

The OCTC - Oncology Clinical and Translational Consortium, a collaborative scientific research network comprised of 6 renowned comprehensive cancer centers, was launched by GSK in 2013.

While GSK gains OCTC's expertise in preclinical, translational and clinical development of novel anticancer therapeutics, the participating centers have access to studies with GSK's early-stage oncology pipeline and opportunities to accelerate and advance the next generation of novel oncology therapeutics.

www.gsk.com

---

New in 2023

---

The Amgen Partners of Choice Network (ApoC) drives academic collaboration through partnerships across the healthcare ecosystem to improve care and advance new treatment options for those patients with the greatest unmet needs. VHIO aims, by collaborating with national and international reference centres,  to achieve effective and individualised treatments to better help those patients with no response towards standard therapies.

In September 2023, Amgen announced its APoC, a consortium comprised of eight research centres renowned for their expertise in oncology research and development, as well as their world-class clinical leaders. The selected ApoC member institutions are Asan Medical Centre (Seoul, South Korea), Dana-Farber Cancer Institute (Boston, Mass.), Essen University Hospital (Essen, Germany), Institute Gustave Roussy (Paris, France), Memorial Sloan Kettering Center (New York, N.Y.), Peter MacCallum Cancer Centre (Melbourne, Australia) Princess Margaret Cancer Centre (Toronto, Canada), and Vall d'Hebron Institute of Oncology (Barcelona, Spain).

This network will serve for the creation of new programs and lines of treatment that lead to the development of new and effective treatments for cancer patients by creating multiple collaboration channels globally. Currently, ApoC projects are mainly focused on selected tumour types including thoracic, gastrointestinal and genitourinary cancers. Amgen, therefore, aims to make profound differences in changing the standard of care and is committed to doing so through the consortium, by helping to foster earlier and more frequent academic collaboration to fuel quicker progress.

https://www.amgen.com